We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vascular Solutions, Inc.(VASC) Stopping Their Red Ink and Bl
VASC 56.000.0%Feb 21 3:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Arthur Radley12/31/2008 3:36:21 PM
   of 22
Report out today from something to consider and make own decision as to how this applies..

We've upgraded Vascular Solutions (VASC Quote - Cramer on VASC - Stock Picks), which develops medical device for interventional cardiologists and radiologists in the United States and internationally, from hold to buy. This upgrade is driven by a few notable strengths, such as the company's robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

VASC Vascular's revenue growth has slightly outpaced the industry average of 15.6%. Since the same quarter one year prior, revenues rose by 17.8%. Growth in the company's revenue appears to have helped boost the earnings per share.
Vascular has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. To add to this, Vascular has a quick ratio of 1.67, which demonstrates the ability of the company to cover short-term liquidity needs.

The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 11380.0% when compared to the same quarter one year prior, rising from $0.02 million to $1.72 million.

Net operating cash flow has significantly increased by 115.42% to $1.19 million when compared to the same quarter last year. In addition, Vascular has also vastly surpassed the industry average cash flow growth rate of 21.71%.

This stock has managed to rise its share value by 35.30% over the past twelve months. Looking ahead, the stock's sharp rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext